SammyJo s MS-LDN Timeline



Similar documents
Survey of 267 Patients Using Low Dose Naltrexone for Multiple Sclerosis

Committee Approval Date: December 12, 2014 Next Review Date: December 2015

Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012

Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012

Medication Policy Manual. Topic: Plegridy, peginterferon beta-1a Date of Origin: December 12, 2014

PCORI Workshop on Treatment for Multiple Sclerosis. Breakout Group Topics and Questions Draft

Relapsing-remitting multiple sclerosis Ambulatory with or without aid

Medication Policy Manual. Topic: Betaseron, Extavia, interferon beta-1b Date of Origin: June 18, 2004

Disease Modifying Therapies for MS

Which injectable medication should I take for relapsing-remitting multiple sclerosis?

Medication Policy Manual. Topic: Gilenya, fingolimod Date of Origin: November 22, 2010

Multiple Sclerosis Drug Discoveries - What the Future Holds

Disease Modifying Therapies for MS

NHS BOURNEMOUTH AND POOLE AND NHS DORSET

SECTION 2. Section 2 Multiple Sclerosis (MS) Drug Coverage

Conflict of Interest Declaration. Overview of New Medications for Multiple Sclerosis. Assessment Question. Objectives 4/1/2011

Disease Modifying Therapies (DMTs) in Multiple Sclerosis

Copaxone for multiple sclerosis (RRMS)

Study Support Materials Cover Sheet

What is Multiple Sclerosis? Gener al information

Integrating New Treatments: A Case Based Approach

Information About Medicines for Multiple Sclerosis

Multiple Sclerosis (MS) Class Update

New and Emerging Immunotherapies for Multiple Sclerosis: Oral Agents

Treatment in Relapsing MS: Choosing Among the Options. Donald Negroski, MD

A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market

Committee Approval Date: December 12, 2014 Next Review Date: December 2015

ORAL MEDICATIONS FOR MS! Gilenya and Aubagio

Multiple Sclerosis (MS) Aprile Royal, Novartis Pharma Canada Inc. September 21, 2011 Toronto, ON

Voting for your top research questions Survey

Disclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics

Interferons (Avonex, Betaferon, Rebif ) for relapsing remitting multiple sclerosis (RRMS)

MSTAC Initial Application

Issues Regarding Use of Placebo in MS Drug Trials. Peter Scott Chin, MD Novartis Pharmaceuticals Corporation

Multiple Sclerosis (MS) is a disease of the central nervous system (including the brain and spinal cord) in which the nerves degenerate.

A blood sample will be collected annually for up to 2 years for JCV antibody testing.

Growth in revenue from MS drugs has been driven largely by price increases over the last several years.

How to S.E.A.R.C.H. SM for the Right MS Therapy For You!

Resources for the Primary Care Provider. Please print these out for reference

Information about medicines for multiple sclerosis

06/06/2012. The Impact of Multiple Sclerosis in the Pacific Northwest. James Bowen, MD. Swedish Neuroscience Institute

Insight. Drug Class. Background, new developments, key strategies. Introduction. Faulty signals. 400,000 patients in the US 1

Clinical Commissioning Policy: Disease Modifying Therapies For patients With Multiple Sclerosis (MS) December Reference : NHSCB/D4/c/1

Understanding Relapse in Multiple Sclerosis

How to S.E.A.R.C.H. for the Right MS Therapy for You!

Version History. Previous Versions. Drugs for MS.Drug facts box fingolimod Version 1.0 Author

Mellen Center for Multiple Sclerosis

Multiple Sclerosis Update. Bridget A. Bagert, MD, MPH Director, Ochsner Multiple Sclerosis Center

Personalised Medicine in MS

Original Policy Date

Novel therapeutic approaches in multiple sclerosis Neuroprotective and remyelinating agents, the future of clinical trials in MS?

Multiple Sclerosis: What You Need To Know. For Professionals

Uncertainty in Benefit and Risk: Tysabri (natalizumab)

CNS DEMYLINATING DISORDERS

Lemtrada (alemtuzumab)

Using the MS Clinical Course Descriptions in Clinical Practice

Supplementary Online Content

A neurologist would assess your eligibility and suitability for the DMTs.

Progress in MS: Current and Emerging Therapies

Multiple Sclerosis. Global Drug Forecast and Market Analysis to 2022 Event-Driven Update. GDHC34PIDR / Published April 2013

Immunoablative therapy with autologous hematopoietic stem cell transplantation in the treatment of poor risk multiple sclerosis

Patients with confirmed relapse (23.4 %) (15.4 %) 1.52 [0.87; 2.67] p = Probability of a relapse by week 96

Version History. Previous Versions. for secondary progressive MS (SPMS) Policy Title. Drugs for MS.Drug facts box Interferon beta 1b

Review Date: March Issue Status: Approved Issue No: 2 Issue Date: March 2010

Talking With Your Doctor About Multiple Myeloma: A guide to making the most of your healthcare visits

How To Use A Drug In Multiple Sclerosis

Rational basis for early treatment in MS. Bonaventura Casanova Estruch Unitat d Esclerosi Múltiple Hospital Universitari la Fe València

National Multiple Sclerosis Society. Disease Modification in Multiple Sclerosis. Current as of January 2, 2013

What is MS? 1. disease that affects the central nervous. Is a disease that affects both white and gray matter

Drug Class Review on Disease-modifying drugs for Multiple Sclerosis

New Treatment Options for MS Patients: Understanding risks versus benefits

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Tysabri

Multiple Sclerosis. Multiple Sclerosis. In addition to help nursing professional to understand the signs and

New Developments in the Treatment and Management of Multiple Sclerosis

Understanding. Multiple Sclerosis. Tim, diagnosed in 2004.

Treating symptoms. An introduction to. Everyone diagnosed with MS can get treatment for their symptoms. The symptoms of MS. Who can get treatment?

Interferons (Avonex, Betaferon, Rebif ) for primary progressive multiple sclerosis (RRMS)

Commissioning Policy: Disease Modifying Therapies for patients with Multiple Sclerosis (MS).

Multiple Sclerosis - Relapsing and Remissioning

Understanding Relapse in Multiple Sclerosis. A guide for people with MS and their families

Version History. Previous Versions. Policy Title. Drugs for MS.Drug facts box Glatiramer Acetate Version 1.0 Author

Clinical Study Synopsis

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal

A Letter From the MS Coalition

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Multiple Sclerosis Agents

Pregnancy and Reproductive Issues in MS. Annette Wundes, MD Co-Director University of Washington MS Center November 12,2014

The MS Disease- Modifying Drugs. Gener al information

Drug Use Research & Management Program Phone Fax Generic Name: Brand Name (Manufacturer): PDL Class: Comparator Therapies: Dossier received:

Literature Scan: Oral Multiple Sclerosis Drugs

this 7^ day of September 2014 by Randall S. Gregg Special Deputy Director

National MS Society Information Sourcebook

Equipment Distribution Program Application 375 Kings Highway North, Cherry Hill, NJ (800) Web:

Advanced Multiple Sclerosis: Progressive MS Epidemiology

Multiple Sclerosis Treatment Experience Questionnaire (MSTEQ)

Grand Rounds: Exploring Current Therapeutic Agents in Multiple Sclerosis Management. CME University, FreeCME.com, Powerpak.com

Multiple Sclerosis & MS Ireland Media Fact Sheet

Multiple sclerosis (MS) is a chronic, neurodegenerative

LIVING WELL An Integrative Approach to Wellness with MS Member Application

DISEASE MODIFYING THERAPY CARE PATHWAY. Multiple Sclerosis Service

Interferons (Avonex, Betaferon, Rebif ) for secondary progressive multiple sclerosis (SPMS)

Transcription:

SammyJo s MS-LDN Timeline Better 1 Stop all other meds 4/4 2 EDSS Disability Scale 3 3 3.5 3.5 3.5 3.5 4 4 4 4 4.5 5 5_ 6 7 8 Start LDN 2/4 6.5 7 9 Worse 1 Steroids Copaxone Novan trone Avonex Steroid 25 24 23 22 21 2 1999 1998 1997 1996 1995 Started RR 95 with full set of symptoms, frequent relapses. Copaxone 98-2, only 1 relapse. SP and Novantrone 22. Got worse the whole time, cane by Feb 3. Please don t let anyone you know try Novantrone chemo for MS until they ve tried LDN. Only made it 1 yr, not 2. My LVEF heart function went down from 6 to 5. FDA just increased warnings. Heart & leukemia risk for the rest of my life. Continued to worsen for 1 months after Novantrone, until starting LDN Feb 24. Immediate improvement 1 st nite - slep for 8 hrs straight first time in years. Put down my cane of 1 yr after 4 weeks. Amazed my neuro. Continuous improvement ever since, can now walk 1 mile.

LDNers.org Survey 1 General Findings Survey 1 Population: 267 Subjects, avg. 1 yrs diagnosis, 65% female Avg. LDN treatment 8 months, 24% 2 years+ of LDN treatment 1%, 28 individuals out of 267, reported a total of 42 relapses,.2 /yr Survey Results: PPms PRms RRms SPms Total Total in MS type 13% 4% 43% 39% 267 Avg Mo's LDN 1 mo 13 mo 7 mo 9 mo 8 mo Relapse Rate.1.2.3.3.2 Subjective Assessments: Symptoms Improved 53% 75% 82% 57% 7% Progression Halt 5% 58% 34% 43% 45% LDN Helps, Will Continue 76% 83% 75% 7% 76% Online surveys Aggregate anecdotal reports into statistical format #1 to help others make informed decision about LDN, since limited medical advice. #2 Serve as an alert for researchers that there is something positive happening with LDN users, and spur research.

LDNers.org Survey 1 Relapse Rate Survey 1 Relapse Rate:.2 relapses per year, or 1 relapse in 5 years Better than the ABC drugs for MS Relapses in 1 Year 1.2 1.8.6.4.2 Untreated Avonex Betaseron Copanone LDN ABC Source: A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy. PMID: 11795454 LDN Source LDNers.org Survey 1, July 24 The low relapse rate reported in the first survey was the most significant finding.

LDNers.org Survey 2 Disability Survey 2 Population: 138 subjects I have contact info for interested researchers 4.27 Avg. EDSS when they began LDN (able to walk about 4 meters) 3.66 Avg. EDSS when they took the survey 2 nd half of 24 Avg. length of LDN treatment 8 months Survey Results: 3 25 n = 138 2 15 1 Start LDN Survey Date 5 1.5 2.5 3.5 4.5 5.5 6.5 7.5 8.5 EDSS EDSS Start LDN Survey Date 3 9 1 9 2 1.5 17 15 2 11 11 2.5 9 7 3 7 12 3.5 5 2 4 8 3 4.5 2 1 5 1 7 5.5 1 8 6 13 9 6.5 27 21 7 4 5 7.5 8 3 8 2 2 8.5 1 9 1 1 Avg. 4.27 3.66

After LDN: MS Recovery LDN halted my disease activity, so recovery could begin It s been hard work, but I can now walk 1 mile These therapies have worked for me: 1. Physical Therapy & Massage 2. Chiropractic 3. Supplements - Omega 3-Fish Oils, cathechians, Co Q1 4. Nanosecond PEMF - Pulsed Electromagnetic Energy See MS Recovery at LDNers.org for details and clinical studies. LDN quickly halted my MS disease progression. Then the hard work began on repair and recovery after years of damage, from MS and the MS drugs that only left me with more disability. Lucky for me my cousin Vicki is an RN rehabilitation specialist, so I've had great guidance on recovery therapies. In return I tipped her off on LDN for fibromyalgia, and now we're both here celebrating our recoveries at the LDN conference! I can now walk one mile, thanks to LDN, followed by: Physical Therapy, Massage, Chiropractic, Supplements and Pulsed Electromagnetic Energy. You've heard about or used the first 4, and your neurologist better be writing PT scripts for you. But PEMF is an important therapy for all LDN advocates to know about because I have helped several MS patients get off pain narcotics so they could start LDN by using PEMF pain management technology instead of drugs. For me, I didn't have severe pain, but PEMF completely restored my heart function after it was degraded by Novantrone. After LDN I lost respect for standard medical protocols and started down the integrative medicine path, especially therapies tested by clinical research. See MS Recovery at LDNers.org for research details.